Baxter International Inc.
BAX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BAX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BAX
Baxter International Inc. is a global medtech company focused on medical products, therapies, and healthcare systems, operating under two segments following the sale of its Kidney Care business and the acquisition of Hillrom.
Key risk: High debt burden
BioSniper Score
Based on 4 of 6 signals
Market Cap
$13.51B
Cash Runway
—
Lead Asset
floseal hemostatic matrix
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 1 clinical trial for Baxter International Inc..
Baxter International Inc. is a global medtech company focused on medical products, therapies, and healthcare systems, operating under two segments following the sale of its Kidney Care business and the acquisition of Hillrom.
- Baxter reported cash & equivalents of $2,150.0M, total revenue of $2,960.0M, net income of $126.0M, and shareholders' equity of $7,320.0M as of 2026-06-30 [sec].
- As of the second quarter of 2026, Baxter operates under two segments: Medical Products & Therapies (MPT) and Healthcare Systems & Technologies (HST), with the former Pharmaceuticals segment now reported within the Infusion Therapies & Platforms division of MPT [news · 2026-07-14].
- Baxter sold its Kidney Care business in January 2025 to repay outstanding indebtedness and is working to realize anticipated benefits from the Hillrom acquisition [sec_mda · as of 2026-02-12].
- The company faces significant indebtedness that constrains cash flow for debt service and limits growth and R&D investment [sec_mda · as of 2026-02-12].
What works
- Baxter has a diversified product portfolio across medical products, therapies, and healthcare systems, with a focus on asset and resource efficiency in the healthcare market [sec_mda · as of 2026-02-12].
- The sale of the Kidney Care business in January 2025 allowed Baxter to repay some outstanding debt, improving its balance sheet [sec_mda · as of 2026-02-12].
- Baxter continues to invest in research and development to introduce new products and maintain its competitive position [sec_mda · as of 2026-02-12].
What to weigh
- Baxter's significant indebtedness requires substantial cash flow for debt service, constraining its ability to pursue growth strategies and advance R&D [sec_mda · as of 2026-02-12].
- The company may not achieve anticipated benefits from the Hillrom acquisition and Kidney Care sale, including cost and revenue synergy targets [sec_mda · as of 2026-02-12].
- Baxter faces intense competition and pricing pressures that could reduce margins and adversely affect financial results [sec_mda · as of 2026-02-12].
- Product development involves substantial investment and inherent risk, and failure to introduce new products could lead to market share loss [sec_mda · as of 2026-02-12].
From the filings
Quoted directly from source documents.
Baxter's significant indebtedness constrains cash flow for debt service and limits growth and R&D investment.
“Our significant indebtedness requires us to use a substantial amount of our cash flow for debt service and constrains our ability to pursue growth strategies and advance our R&D capabilities.”
SEC MD&A · February 12, 2026
Baxter sold its Kidney Care business in January 2025 to repay debt.
“As part of our strategy to realign our product portfolio, we sold our Kidney Care business in January 2025. While the sale allowed us to repay some of our outstanding indebtedness”
SEC MD&A · February 12, 2026
Baxter began reporting under two segments starting in Q2 2026.
“Starting in the second quarter of 2026, the Company began reporting under the following two segments: Medical Products & Therapies (MPT); and Healthcare Systems & Technologies (HST).”
News · July 14, 2026
Baxter faces risks from competition and pricing pressures.
“There is substantial competition in the product markets in which we operate and the risk of declining demand and pricing pressures could adversely affect our business, results of operations, financial condition and cash flows.”
SEC MD&A · February 12, 2026
Risks & what to watch (4)›
Key risks
- High debt burden — Significant indebtedness requires substantial cash flow for debt service, constraining growth and R&D [sec_mda · as of 2026-02-12].
- Integration and synergy risks — May not achieve anticipated benefits from Hillrom acquisition and Kidney Care sale [sec_mda · as of 2026-02-12].
- Intense competition — Competition and pricing pressures could reduce margins and market share [sec_mda · as of 2026-02-12].
- Product development risk — R&D requires substantial investment and may not yield successful products [sec_mda · as of 2026-02-12].
What to watch
- Progress on realizing cost and revenue synergies from the Hillrom acquisition [sec_mda · as of 2026-02-12].
- Ability to manage debt levels and cash flow for debt service [sec_mda · as of 2026-02-12].
- Performance of new reporting segments (MPT and HST) and product portfolio optimization [news · 2026-07-14].
- Impact of competitive dynamics and pricing pressures on margins [sec_mda · as of 2026-02-12].
Sources: News · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Baxter International Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Baxter International Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 2.19 · 0% dilution
Lead: Approved
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
661
Total value held
$9.15B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 79,400,664 | $1.33B |
| vanguard capital management llc | 67,013,950 | $1.13B |
| pzena investment management llc | 64,527,823 | $1.08B |
| dodge & cox | 57,254,570 | $961.9M |
| fmr llc | 46,264,804 | $777.2M |
| vanguard portfolio management llc | 23,993,355 | $403.1M |
| state street corp | 19,979,957 | $335.9M |
| greenhaven associates inc | 14,307,688 | $240.4M |
| geode capital management, llc | 13,762,965 | $230.8M |
| morgan stanley | 7,347,972 | $123.4M |
Showing top 10 of 661 institutional holders of Baxter International Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 10.7%
- Days to cover
- 4.5
- Shares short
- 35,078,391
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BAX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Baxter International Inc.?
Baxter International Inc. is a global medtech company focused on medical products, therapies, and healthcare systems, operating under two segments following the sale of its Kidney Care business and the acquisition of Hillrom.
Who is the CEO of Baxter International Inc.?
Mr. Andrew P. Hider is the chief executive officer of Baxter International Inc. (BAX).
Where is Baxter International Inc. headquartered?
Baxter International Inc. (BAX) is headquartered in Deerfield, IL, United States.
What therapeutic areas does Baxter International Inc. focus on?
Baxter International Inc. develops therapies across Oncology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.